AD
Antal Rohit Desai (Director) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in PROCEPT BioRobotics Corporation (PRCT). Across 1 priced purchase filing, the average 21-session return was -4.6% from execution and -2.6% from disclosure (delay-adjusted; derived). The largest single filing was $10.4M of PRCT (424,962 sh across 6 lots, as filed), executed Mar 5. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
-4.6%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
-2.6%
same 1 filings, from disclosure
Filings, ttm
1
1 buys · 0 sells
Median delay
4d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$10.4M
shares × price, as filed
Last traded
Mar 9
Filed Mar 9
Median ADV $35.5M across their filed names
Open performance→Volume by month
Buys $10.4M
Sells $9.1M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
1 filing
Sector per market data · by filing · past 12 months
Most traded names
PRCT
PROCEPT BioRobotics Corporation
PRCT · 1 buy · 2 sells
3 filings
Recent filings
PRCTPURCHASE
PROCEPT BioRobotics Corporation
View filing →
$10.4M424,962 sh across 6 lots
Exec Mar 5
Filed Mar 9 · 7:19 PM ET PRCTSALE PROCEPT BioRobotics Corporation View filing → $4.7M
75,000 sh across 8 lots
Exec Jun 10 2025
Filed Jun 12 2025 · 5:30 PM ET PRCTSALE PROCEPT BioRobotics Corporation View filing → $4.4M
70,682 sh across 8 lots
Exec Jun 3 2025
Filed Jun 5 2025 · 5:30 PM ET PRCTSALE PROCEPT BioRobotics Corporation View filing → $9.6M
99,500 sh across 11 lots
Exec Nov 5 2024
Filed Nov 7 2024 · 5:30 PM ET